Fecal Transplant Increases Peanut Tolerance
Analysis based on 10 articles · First reported Aug 05, 2026 · Last updated Aug 25, 2026
The findings could spur investment in microbiome-based therapies for food allergies, potentially benefiting biotech companies developing such treatments. However, the small trial size and preliminary nature mean significant market impact is unlikely in the near term.
A phase 1 clinical trial at Boston Children s Hospital, published in Science Translational Medicine, tested whether fecal microbiome transplantation (FMT) could increase peanut tolerance in adults with severe peanut allergies. Fifteen participants received oral encapsulated FMT from healthy donors; six showed increased tolerance, with some tolerating up to 600 mg of peanut protein. The study identified a mechanism involving bile acid metabolites and RORγt+ regulatory T cells, and mouse experiments confirmed the protective effect. Researchers plan a phase 2 trial with a purified formulation. Experts caution that larger studies are needed before clinical use.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard